newsfilter
← Latest News
GlobeNewswire·

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster late-stage drug